Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 20, 2024

Addition of Parsaclisib to Ruxolitinib in Patients With Intermediate or High-Risk Myelofibrosis With Suboptimal Response to Ruxolitinib Monotherapy

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results
Blood Adv 2024 Jan 30;[EPub Ahead of Print], A Yacoub, U Borate, RK Rampal, H Ali, ES Wang, AT Gerds, GS Hobbs, M Kremyanskaya, EF Winton, C O'Connell, S Goel, ST Oh, GJ Schiller, J McCloskey, JM Palmer, H Holmes, S Hager, A Assad, S Erickson-Viitanen, F Zhou, NG Daver

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading